查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1549989

轻度认知障碍的全球市场:疾病类型·年龄·适应症·治疗方法·不同地区的预测 (～2032年)

Global Mild Cognitive Impairment Market Research Report By Disease Type, By Age, By Indication, By Treatment, And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032
出版日期: | 出版商: Market Research Future | 英文 153 Pages | 订单完成后即时交付

价格

轻度认知障碍市场规模预计到 2032 年为 32.5 亿美元，预测期内复合年增长率为 5.95，从 2023 年的 19.4 亿美元和 2024 年的 20.5 亿美元增长到 2032 年。

轻度认知障碍市场的主要推动因素是全球范围内轻度认知障碍的盛行率不断上升以及人们对轻度认知障碍的认识不断增强。儘管轻度认知障碍早期诊断的技术发展预计将带来利润丰厚的市场前景，但多种药物和合併症的控制使治疗方案变得复杂，预计也会减缓全球市场的成长。

区域见解

北美市场在 2022 年占据最大市场占有率，为 42.60%，预计在预测期内复合年增长率为 4.97%，到 2032 年达到约 13.1 亿美元的规模。此外，预计亚太地区在预测期内将以 6.91% 的复合年增长率增长最快。预计未来北美轻度认知障碍市场将稳定成长。对医疗基础设施的投资和对现代医疗解决方案认识的提高预计将进一步推动市场成长。现有企业和新进业者都准备好透过改进技术来利用这一潜力，以满足对更好手术结果日益增长的需求。

由于技术进步、医疗成本上升以及轻度认知障碍负担增加，欧洲市场占据第二大市场。德国预计将拥有最大的市场占有率，而英国预计将成为欧洲成长最快的国家。

本报告调查了全球轻度认知障碍市场，提供了市场的定义和概述，分析了市场成长的各种影响因素、市场规模的趋势和预测、各个细分市场和地区的细分以及竞争。

目录

第1章 摘要整理

第2章 市场概要

第3章 调查手法

第4章 市场动态

  • 促进因素
    • 全球轻度认知障碍负担日益加重
    • 提高对轻度认知障碍的认识
  • 抑制因素
    • 由于多重用药和合併症管理而导致复杂的治疗策略
  • 机会
    • 轻度认知障碍早期诊断技术的进步

第5章 市场要素分析

  • 波特的五力分析
  • COVID-19影响

第6章 全球轻度认知障碍市场:各疾病类型

  • 概要
  • 健忘性轻度认知障碍
  • 非健忘性轻度认知障碍

第7章 全球轻度认知障碍市场:各年龄

  • 概要
  • 儿童
  • 成人
  • 老年人

第8章 全球轻度认知障碍市场:各适应症

  • 概要
  • 路易氏体失智症
  • 帕金森氏症失智症
  • 阿兹海默症
  • 血管性失智症
  • 其他

第9章 全球轻度认知障碍市场:不同治疗

  • 概要
  • 药物
    • 胆碱酯[酉每]抑制剂
    • 苯二氮平类
    • 麸胺酸抑制剂
    • 抗组织胺药
    • MAO抑制剂
    • 质子帮浦抑制剂
    • 其他
  • 治疗
    • 认识刺激疗法
    • 认知行为治疗(CBT)

第10章 全球轻度认知障碍市场:各地区

  • 概要
  • 北美
  • 欧洲
  • 亚太地区
  • 其他地区

第11章 竞争情形

  • 市场占有率分析
  • 竞争仪表板
  • 上市公司的股票概要
  • 比较分析:主要企业的财务趋势
  • 主要的展开·成长策略

第12章 企业简介

  • JOHNSON & JOHNSON SERVICES, INC
  • PFIZER INC
  • NOVARTIS AG
  • ABBVIE INC.
  • BIOGEN
  • EISAI CO., LTD.
  • AUROBINDO PHARMA
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • TAJ PHARMACEUTICALS LTD.

第13章 资料的引用

Product Code: MRFR/HC/9432-CR

Global Mild Cognitive Impairment Market Research Report By Disease Type (Amnestic MCI and Non-Amnestic MCI), By Age (Child, Adult, Geriatric), By Indication (Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia, and Others) By Treatment (Medication (Cholinesterase Inhibitors, Benzodiazepines, Glutamate Inhibitors, Antihistamines, Mao Inhibitors, Proton Pump Inhibitors, and Others), Therapy (Cognitive Stimulation Therapy, Cognitive Behavioural Therapy (CBT)), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World - Forecast Till 2032

Market Overview

The market size for mild cognitive impairment was estimated to be USD 1.94 billion in 2023. The global mild cognitive impairment industry is expected to expand from USD 2.05 billion in 2024 to USD 3.25 billion by 2032, with a compound annual growth rate (CAGR) of 5.95% during the forecast period (2024-2032).

The growing prevalence of mild cognitive impairment around the world, as well as increased awareness of mild cognitive impairment, are the primary drivers of the Mild Cognitive Impairment Market. However, polypharmacy and controlling comorbidities complicate treatment options, which is projected to slow worldwide market growth. Nonetheless, technological developments in the early diagnosis of MCI around the world are expected to provide profitable market prospects. The rising global prevalence of moderate cognitive impairment (MCI) is a primary driver of the global MCI treatment industry.

Marketing Segmentation

Mild Cognitive Impairment Market Segmentation by Disease Type, Amnestic MCI, and Non-Amnestic MCI.

The mild cognitive impairment market segmentation by age comprises child, adult, and geriatric.

The Mild Cognitive Impairment Market has been classified according to indication: Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, vascular dementia, and others.

The Mild Cognitive Impairment Market has been divided into two segments: medicine and therapy.

Regional insights

The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American mild cognitive impairment market had the greatest market share of 42.60% in 2022 and is expected to reach roughly USD 01.31 billion by 2032, growing at a 4.97% CAGR over the forecast period. However, Asia-Pacific is expected to develop at the fastest CAGR of 6.91% over the forecast period. The North American mild cognitive impairment market is expected to increase steadily in the future. Investments in healthcare infrastructure and increased awareness of modern medical solutions are projected to propel market growth even further. Both established firms and new entrants are ready to seize these possibilities, utilizing technological improvements to address the growing need for better surgical outcomes.

Europe's mild cognitive impairment market accounted for the second-largest market share due to technological improvements, rising healthcare costs, and an increased burden of mild cognitive impairment. Furthermore, the German mild cognitive impairment market is expected to have the biggest market share, with the UK mild cognitive impairment market forecast to be the fastest expanding market in Europe.

The Asia-Pacific mild cognitive impairment market is predicted to develop the fastest from 2024 to 2032, owing to a large patient population, an increasing number of mild cognitive cases, and favorable regulatory regulations. Furthermore, prominent companies in the mild cognitive impairment market are aggressively expanding into this region, propelling the regional market forward. Furthermore, China's mild cognitive impairment market had the greatest market share, while India's mild cognitive impairment market is expected to be the fastest expanding in the Asia-Pacific region.

Major Players

Key players in the mild cognitive impairment market include Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), AbbVie Inc. (US), Biogen (Switzerland), Eisai Co., Ltd. (Japan), Aurobindo Pharma (India), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), and Taj Pharmaceuticals Limited (India).

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA FLOW
    • 3.2.1 Data Mining Process
  • 3.3 PURCHASED DATABASE:
  • 3.4 SECONDARY SOURCES:
    • 3.4.1 Secondary Research data flow:
  • 3.5 PRIMARY RESEARCH:
    • 3.5.1 Primary Research DATA FLOW:
    • 3.5.2 Primary Research: Number of Interviews conducted
  • 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
    • 3.6.1 Revenue Analysis Approach
  • 3.7 DATA FORECASTING
    • 3.7.1 Data forecasting Technique
  • 3.8 DATA MODELLING
    • 3.8.1 Microeconomic Factor Analysis:
    • 3.8.2 Data MODELLING:
  • 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 Increasing burden of Mild cognitive impairment across the globe
    • 4.2.2 Rising awareness associated with mild cognitive impairment
  • 4.3 RESTRAINTS
    • 4.3.1 Polypharmacy and managing comorbidities complicate treatment strategies
  • 4.4 OPPORTUNITY
    • 4.4.1 Technological advancements for early diagnosis of MCI

5 MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S FIVE FORCES MODEL
    • 5.1.1 Threat of New Entrants
    • 5.1.2 BARGAINING POWER OF SUPPLIERS
    • 5.1.3 Threat of Substitutes
    • 5.1.4 Bargaining Power of Buyers
    • 5.1.5 Intensity of Rivalry
  • 5.2 IMPACT OF COVID-19 ON THE GLOBAL MILD COGNITIVE IMPAIRMENT MARKET

6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE

  • 6.1 OVERVIEW
  • 6.2 AMNESTIC MCI
  • 6.3 NON-AMNESTIC MCI

7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE

  • 7.1 OVERVIEW
  • 7.2 CHILD
  • 7.3 ADULT
  • 7.4 GERIATRIC

8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION

  • 8.1 OVERVIEW
  • 8.2 LEWY BODY DEMENTIA
  • 8.3 PARKINSON'S DISEASE DEMENTIA
  • 8.4 ALZHEIMER'S DISEASE
  • 8.5 VASCULAR DEMENTIA
  • 8.6 OTHERS

9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT

  • 9.1 OVERVIEW
  • 9.2 MEDICATION
    • 9.2.1 Cholinesterase Inhibitors
    • 9.2.2 Benzodiazepines
    • 9.2.3 Glutamate Inhibitors
    • 9.2.4 Antihistamines
    • 9.2.5 Mao Inhibitors
    • 9.2.6 Proton Pump Inhibitors
    • 9.2.7 Others
  • 9.3 THERAPY
    • 9.3.1 Cognitive Stimulation Therapy
    • 9.3.2 Cognitive Behavioural Therapy (CBT)

10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION

  • 10.1 OVERVIEW
  • 10.2 NORTH AMERICA
    • 10.2.1 us
    • 10.2.2 canada
  • 10.3 EUROPE
    • 10.3.1 Germany
    • 10.3.2 France
    • 10.3.3 UK
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 ASIA-PACIFIC
    • 10.4.1 China
    • 10.4.2 India
    • 10.4.3 Japan
    • 10.4.4 South Korea
    • 10.4.5 AUSTRALIA
    • 10.4.6 Rest of Asia-Pacific
  • 10.5 REST OF THE WORLD
    • 10.5.1 Middle East & Africa
    • 10.5.2 Latin America

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 MARKET SHARE ANALYSIS,
  • 11.3 COMPETITOR DASHBOARD
  • 11.4 PUBLIC PLAYERS STOCK SUMMARY
  • 11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
  • 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 11.6.1 product launch / Product approval

12 COMPANY PROFILES

  • 12.1 JOHNSON & JOHNSON SERVICES, INC
    • 12.1.1 COMPANY OVERVIEW
    • 12.1.2 FINANCIAL OVERVIEW
    • 12.1.3 productS OFFERED
    • 12.1.4 KEY DEVELOPMENTS
    • 12.1.5 SWOT ANALYSIS
    • 12.1.6 KEY STRATEGIES
  • 12.2 PFIZER INC
    • 12.2.1 COMPANY OVERVIEW
    • 12.2.2 FINANCIAL OVERVIEW
    • 12.2.3 productS OFFERED
    • 12.2.4 KEY DEVELOPMENTS
    • 12.2.5 SWOT ANALYSIS
    • 12.2.6 KEY STRATEGIES
  • 12.3 NOVARTIS AG
    • 12.3.1 COMPANY OVERVIEW
    • 12.3.2 FINANCIAL OVERVIEW
    • 12.3.3 productS OFFERED
    • 12.3.4 KEY DEVELOPMENTS
    • 12.3.5 SWOT ANALYSIS
    • 12.3.6 KEY STRATEGIES
  • 12.4 ABBVIE INC.
    • 12.4.1 COMPANY OVERVIEW
    • 12.4.2 FINANCIAL OVERVIEW
    • 12.4.3 PRODUCTS OFFERED
    • 12.4.4 KEY DEVELOPMENTS
    • 12.4.5 SWOT ANALYSIS
    • 12.4.6 KEY STRATEGIES
  • 12.5 BIOGEN
    • 12.5.1 COMPANY OVERVIEW
    • 12.5.2 FINANCIAL OVERVIEW
    • 12.5.3 PRODUCTS OFFERED
    • 12.5.4 KEY DEVELOPMENTS
    • 12.5.5 KEY STRATEGIES
  • 12.6 EISAI CO., LTD.
    • 12.6.1 COMPANY OVERVIEW
    • 12.6.2 FINANCIAL OVERVIEW
    • 12.6.3 PRODUCTS OFFERED
    • 12.6.4 KEY DEVELOPMENTS
    • 12.6.5 KEY STRATEGIES
  • 12.7 AUROBINDO PHARMA
    • 12.7.1 COMPANY OVERVIEW
    • 12.7.2 FINANCIAL OVERVIEW
    • 12.7.3 PRODUCTS OFFERED
    • 12.7.4 KEY DEVELOPMENTS
    • 12.7.5 KEY STRATEGIES
  • 12.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 12.8.1 COMPANY OVERVIEW
    • 12.8.2 FINANCIAL OVERVIEW
    • 12.8.3 PRODUCTS OFFERED
    • 12.8.4 KEY DEVELOPMENTS
    • 12.8.5 SWOT ANALYSIS
    • 12.8.6 KEY STRATEGIES
  • 12.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 12.9.1 COMPANY OVERVIEW
    • 12.9.2 FINANCIAL OVERVIEW
    • 12.9.3 PRODUCTS OFFERED
    • 12.9.4 KEY DEVELOPMENTS
    • 12.9.5 KEY STRATEGIES
  • 12.10 TAJ PHARMACEUTICALS LTD.
    • 12.10.1 COMPANY OVERVIEW
    • 12.10.2 FINANCIAL OVERVIEW
    • 12.10.3 PRODUCTS OFFERED
    • 12.10.4 KEY DEVELOPMENTS
    • 12.10.5 KEY STRATEGIES

13 DATA CITATIONS

LIST OF TABLES

  • TABLE 1 QFD MODELLING FOR MARKET SHARE ASSESSMENT
  • TABLE 2 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 3 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR AMNESTIC MCI, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 4 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR NON-AMNESTIC MCI, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 5 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR CHILD, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR ADULT, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR GERIATRIC, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR LEWY BODY DEMENTIA, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 11 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR PARKINSON'S DISEASE DEMENTIA, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 12 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR ALZHEIMER'S DISEASE, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 13 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR VASCULAR DEMENTIA, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 14 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 15 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 16 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 17 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 18 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR CHOLINESTERASE INHIBITORS, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 19 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR BENZODIAZEPINES, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 20 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR GLUTAMATE INHIBITORS, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 21 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR ANTIHISTAMINES, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 22 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR MAO INHIBITORS, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 23 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR PROTON PUMP INHIBITORS, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 24 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 25 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 26 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 27 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR COGNITIVE STIMULATION THERAPY, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 28 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, FOR COGNITIVE BEHAVIOURAL THERAPY (CBT), BY REGION, 2019-2032 (USD BILLION)
  • TABLE 29 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 30 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
  • TABLE 31 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 32 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 33 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 34 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 35 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 36 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 37 US MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 38 US MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 39 US MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 40 US MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 41 US MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 42 US MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 43 CANADA MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 44 CANADA MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 45 CANADA MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 46 CANADA MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 47 CANADA MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 48 CANADA MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 49 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
  • TABLE 50 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 51 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 52 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 53 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 54 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 55 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 56 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 57 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 58 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 59 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 60 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 61 GERMANY MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 62 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 63 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 64 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 65 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 66 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 67 FRANCE MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 68 UK MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 69 UK MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 70 UK MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 71 UK MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 72 UK MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 73 UK MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 74 ITALY MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 75 ITALY MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 76 ITALY MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 77 ITALY MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 78 ITALY MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 79 ITALY MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 80 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 81 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 82 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 83 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 84 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 85 SPAIN MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 86 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 87 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 88 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 89 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 90 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 91 REST OF EUROPE MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE 2019-2032 (USD BILLION)
  • TABLE 92 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
  • TABLE 93 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 94 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 95 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 96 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 97 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 98 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 99 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 100 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 101 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 102 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 103 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 104 CHINA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 105 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 106 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 107 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 108 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 109 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 110 INDIA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 111 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 112 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 113 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 114 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 115 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 116 JAPAN: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 117 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 118 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 119 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 120 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 121 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 122 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 123 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 124 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 125 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 126 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 127 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 128 AUSTRALIA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 129 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 130 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 131 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 132 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 133 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 134 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 135 REST OT THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY REGION, 2019-2032 (USD BILLION)
  • TABLE 136 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 137 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 138 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 139 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 140 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 141 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 142 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 143 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 144 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 145 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 146 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 147 MIDDLE EAST & AFRICA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 148 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2019-2032 (USD BILLION)
  • TABLE 149 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2019-2032 (USD BILLION)
  • TABLE 150 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2019-2032 (USD BILLION)
  • TABLE 151 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
  • TABLE 152 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 153 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT MARKET, FOR THERAPY, BY TYPE, 2019-2032 (USD BILLION)
  • TABLE 154 PUBLIC PLAYERS STOCK SUMMARY
  • TABLE 155 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
  • TABLE 156 PRODUCT LAUNCH/ PRODUCT APPROVAL
  • TABLE 157 JOHNSON & JOHNSON SERVICES, INC: PRODUCT OFFERED
  • TABLE 158 PFIZER INC: PRODUCT OFFERED
  • TABLE 159 NOVARTIS AG: PRODUCT OFFERED
  • TABLE 160 ABBVIE INC.: PRODUCTS OFFERED
  • TABLE 161 BIOGEN: PRODUCTS OFFERED
  • TABLE 162 BIOGEN: KEY DEVELOPMENTS
  • TABLE 163 EISAI CO., LTD.: PRODCUTS OFFERED
  • TABLE 164 EISAI CO., LTD.: KEY DEVELOPMENTS
  • TABLE 165 AUROBINDO PHARMA: PRODCUTS OFFERED
  • TABLE 166 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
  • TABLE 167 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODCUTS OFFERED
  • TABLE 168 TAJ PHARMACEUTICALS LTD.: PRODUCTS OFFERED

LIST OF FIGURES

  • FIGURE 1 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET: STRUCTURE
  • FIGURE 2 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
  • FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
  • FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)
  • FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL MILD COGNITIVE IMPAIRMENT MARKET
  • FIGURE 6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE, 2022 & 2032 (USD BILLION)
  • FIGURE 7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY DISEASE TYPE,
  • FIGURE 8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE, 2022 & 2032 (USD BILLION)
  • FIGURE 9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY AGE,
  • FIGURE 10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION, 2022 & 2032 (USD BILLION)
  • FIGURE 11 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY INDICATION,
  • FIGURE 12 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT, 2022 & 2032 (USD BILLION)
  • FIGURE 13 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY TREATMENT,
  • FIGURE 14 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION, 2022 & 2032 (USD BILLION)
  • FIGURE 15 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY REGION,
  • FIGURE 16 NORTH AMERICA MARKET ANALYSIS: MILD COGNITIVE IMPAIRMENT MARKET, 2019-2032 (USD BILLION)
  • FIGURE 17 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
  • FIGURE 18 NORTH AMERICA MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY COUNTRY,
  • FIGURE 19 EUROPE MARKET ANALYSIS: MILD COGNITIVE IMPAIRMENT MARKET, 2019-2032 (USD BILLION)
  • FIGURE 20 EUROPE MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
  • FIGURE 21 EUROPE MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY COUNTRY,
  • FIGURE 22 ASIA-PACIFIC MARKET ANALYSIS: MILD COGNITIVE IMPAIRMENT MARKET, 2019-2030 (USD BILLION)
  • FIGURE 23 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET, BY COUNTRY, 2022 & 2030 (USD BILLION)
  • FIGURE 24 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY COUNTRY,
  • FIGURE 25 REST OF THE WORLD MARKET ANALYSIS: MILD COGNITIVE IMPAIRMENT MARKET, 2019-2030 (USD BILLION)
  • FIGURE 26 REST OT THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET, BY REGION, 2022 & 2030 (USD BILLION)
  • FIGURE 27 REST OT THE WORLD: MILD COGNITIVE IMPAIRMENT MARKET SHARE (%), BY REGION,
  • FIGURE 28 MILD COGNITIVE IMPAIRMENT MARKET PLAYERS: COMPETITIVE ANALSIS,
  • FIGURE 29 COMPETITOR DASHBOARD: GLOBAL MILD COGNITIVE IMPAIRMENT MARKET
  • FIGURE 30 JOHNSON & JOHNSON SERVICES, INC: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 31 JOHNSON & JOHNSON SERVICES, INC: SWOT ANALYSIS
  • FIGURE 32 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 33 PFIZER INC: SWOT ANALYSIS
  • FIGURE 34 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 35 NOVARTIS AG: SWOT ANALYSIS
  • FIGURE 36 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 37 ABBVIE INC.: SWOT ANALYSIS
  • FIGURE 38 BIOGEN: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 39 EISAI CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 40 AUROBINDO PHARMA: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 41 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW
  • FIGURE 42 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
  • FIGURE 43 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT